The report included interviews with uterine fibroid patient Stephanie Small and University of Virginia radiologist Alan Matsumoto, MD.
Commenting on future uses of the technology of MR guided focused ultrasound, Brad Wood, MD, of the NIH Center for Interventional Oncology, said "We will see a day in the coming five years where this treatment is playing a major role for the cancer patient."
Currently, ExAblate is used to treat uterine fibroids, with over 7500 women successfully treated.
Research facilities worldwide are studying the MR guided focused ultrasound technology to treat a variety of cancer including prostate and bone cancer, as well as, other conditions such as epilepsy and Parkinson’s disease
Click here to watch the video & view the report.